SSY Group Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jiguang Qu

Chief Executive Officer (CEO)

HK$6.7m

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	16.8yrs
Participación del CEO	9.6%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jiguang Qu en comparación con los beneficios de SSY Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	HK$7m	HK$7m	HK$1b
Sep 30 2023	n/a	n/a	HK$1b
Jun 30 2023	n/a	n/a	HK$1b
Mar 31 2023	n/a	n/a	HK$1b
Dec 31 2022	HK$15m	HK$7m	HK$1b
Sep 30 2022	n/a	n/a	HK$1b
Jun 30 2022	n/a	n/a	HK$1b
Mar 31 2022	n/a	n/a	HK$933m
Dec 31 2021	HK$7m	HK$7m	HK$786m
Sep 30 2021	n/a	n/a	HK$713m
Jun 30 2021	n/a	n/a	HK$641m
Mar 31 2021	n/a	n/a	HK$626m
Dec 31 2020	HK$7m	HK$7m	HK$612m
Sep 30 2020	n/a	n/a	HK$723m
Jun 30 2020	n/a	n/a	HK$835m
Mar 31 2020	n/a	n/a	HK$985m
Dec 31 2019	HK$13m	HK$6m	HK$1b
Sep 30 2019	n/a	n/a	HK$1b
Jun 30 2019	n/a	n/a	HK$1b
Mar 31 2019	n/a	n/a	HK$963m
Dec 31 2018	HK$17m	HK$6m	HK$912m
Sep 30 2018	n/a	n/a	HK$867m
Jun 30 2018	n/a	n/a	HK$822m
Mar 31 2018	n/a	n/a	HK$743m
Dec 31 2017	HK$12m	HK$6m	HK$665m

Compensación vs. Mercado: La compensación total de Jiguang($USD853.76K) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD552.33K).

Compensación vs. Ingresos: La compensación de Jiguang ha sido consistente con los resultados de la empresa en el último año.

CEO

Jiguang Qu (68 yo)

16.8yrs

Permanencia

HK$6,690,000

Compensación

Mr. Jiguang Qu has been the Chairman and General Manager of Shijiazhuang Siyao Pharmaceutical Ltd. from January 2000. Mr. Qu serves as the Chairman and Chief Executive Officer of SSY Group Limited.He is...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jiguang Qu	Chairman & CEO	16.8yrs	HK$6.69m	9.6% HK$ 1.3b
Hing Yeung Chow	CFO, Company Secretary & Executive Director	2.8yrs	HK$1.10m	sin datos
Xuejun Su	Executive Director	9.4yrs	HK$1.72m	0.82% HK$ 112.6m
Guo Meng	Deputy GM & Executive Director	2.8yrs	HK$1.22m	sin datos
Kwok Wai Chow	Independent Non Executive Director	18.6yrs	HK$228.00k	sin datos
Yibing Wang	Independent Non Executive Director	16.8yrs	HK$228.00k	sin datos
Guangce Jiang	Independent Non-Executive Director	1.3yrs	HK$228.00k	sin datos
Wenjun Liu	Non-Executive Director	less than a year	sin datos	sin datos

6.1yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de 2005 se considera experimentada (6 años de antigüedad promedio).

SSY Group Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Chairman & CEO recently bought HK$2.5m worth of stock

SSY Group Limited, Annual General Meeting, May 17, 2024

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Chairman & CEO recently bought HK$4.7m worth of stock

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

Chairman & CEO recently bought HK$8.3m worth of stock

Recent updates

Upcoming dividend of HK$0.10 per share

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$2.5m worth of stock

SSY Group Limited, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: EPS: HK$0.44 (vs HK$0.38 in FY 2022)

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$4.7m worth of stock

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection

SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

Upcoming dividend of HK$0.07 per share at 3.5% yield

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022)

Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023

SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China

SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension

Chairman & CEO recently bought HK$8.3m worth of stock

SSY Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee

Upcoming dividend of HK$0.08 per share at 2.8% yield

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

Chairman & CEO recently bought HK$4.9m worth of stock

SSY Group Limited Announces Update on Product Development

Chairman & CEO recently bought HK$2.1m worth of stock

Full year 2022 earnings released: EPS: HK$0.38 (vs HK$0.26 in FY 2021)

Now 21% undervalued

SSY Group Limited Announces the Group's Tinidazole Obtains the Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Updates on Product Development

SSY Group Limited Obtains the Approval for Registration from the National Medical Products Administration of China to Become A Bulk Drug for the Preparations on the Market

SSY Group Limited Obtains Approvals for Drug Production and Registration for Felodipine Sustained-Release Tablets (5mg) and Lacosamide Injection (20ml:0.2g) from the National Medical Products Administration of China

Investor sentiment improved over the past week

SSY Group Limited Announces Appointment of Jiang Guangce as an Independent Non-Executive Director and Member of Audit Committee, Nomination Committee and Remuneration Committee, with Effect from 1 January 2023

Less than half of directors are independent

SSY Group Limited Obtains the Approval for Drug Production and Registration for Azithromycin Tablets (0.25G) from the National Medical Products Administration of China, Being Under Type 4 Chemical Drug and Regarded as Passing the Consistency Evaluation

SSY Group Limited Obtains the Approval for Drug Productions from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development